In our study group, patients with DNMT3A mutations had worse outcomes than those with wild-type DNMT3A. Hou et al. [28] and Ribeiro et al. [29] have similarly demonstrated that DNMT3A mutations are independent predictors of shorter OS in patients with de novo AML. Here, DNMT3A is linked to acute myeloid leukemia.